Evidence map›Paper›PMID 32922114›Full record

ArticleClinical Medicine Insights. Oncology2020

Genetic Heterogeneity Between Paired Primary and Brain Metastases in Lung Adenocarcinoma.

Li Li, Zhulin Liu, Rui Han, Lin Li, Mengyao Wang, Depei Huang, Yong He

Open access · goldAbstract read
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Li LiDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, P.R. China.
Zhulin LiuDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, P.R. China.
Rui HanDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, P.R. China.
Lin LiDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, P.R. China.
Mengyao WangDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, P.R. China.
Depei HuangThe Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
Yong HeDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, P.R. China.ORCID https://orcid.org/0000-0002-9404-798X
Army Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAbout one-third of nonsmall cell lung cancer (NSCLC) patients develop brain metastases (BM). However, there is an unmet need for early diagnosis and treatment of BM. The precise mechanism for BM is still unknown. However, the genetic heterogeneity between primary tumor and paired BM indicates that sampling from the primary tumor may not be able to fully represent the mutational status in metastases. In this study, the genetic heterogeneity of primary lung adenocarcinoma and paired BM was analyzed. PATIENTS AND

methodsA total of 11 paired samples of primary tumors and BM from lung cancer patients were included, in which 7 paired samples of patients were finally analyzed. Samples were sequenced by whole-exome sequencing (WES) to investigate the common and unique mutations in the primary tumors and BM, and the similarities and differences in copy number variation (CNV).

resultsThe consistency of gene mutation between primary lung adenocarcinoma and paired BM was 33% to 86%. FAM129C and ADAMTSs specifically mutated in BM, along with NKX2-1 high amplification and SAMD2/4 copy number deletion.

conclusionThe consistency of gene mutation between primary lung adenocarcinoma and corresponding BM is relatively high, while the individual differences were significant. FAM129C and ADAMTSs mutations and high amplification of NKX2-1 may be related to BM of lung cancer. The loss of copy number of SAMD2/4 may be a potential therapeutic target for BM from lung adenocarcinoma.

Indexed as

brain metastasesheterogeneityLung adenocarcinomaprimary

Identifiers

PMID32922114
PMCPMC7450461
OpenAlexW3081486834

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.